Author Correction: Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system
International Journal of Clinical Pharmacy · 2024-06 · 46 (3) · 776-776
DOI: 10.1007/s11096-024-01728-8 ↗Kurz gefasst
Korrektur in der Zeitschrift International Journal of Clinical Pharmacy, online erschienen am 17.04.2024. Verfasst von Wanlong Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China.
- School of Pharmaceutical, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
- Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China. zhuangwei1333@gmail.com.
Zitieren
APA
Lin, W., Xu, J., Liao, Y., Lin, X., Yang, J., & Zhuang, W. (2024). Author Correction: Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system. International Journal of Clinical Pharmacy, 46(3), 776-776. https://doi.org/10.1007/s11096-024-01728-8
Vancouver
Lin W, Xu J, Liao Y, Lin X, Yang J, Zhuang W. Author Correction: Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system. International Journal of Clinical Pharmacy. 2024;46(3):776-776. doi:10.1007/s11096-024-01728-8
BibTeX
@article{Lin2024,
author = {Lin, Wanlong and Xu, Jiabing and Liao, Yufang and Lin, Xiuxian and Yang, Jianhui and Zhuang, Wei},
title = {Author Correction: Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system},
journal = {International Journal of Clinical Pharmacy},
year = {2024},
volume = {46},
number = {3},
pages = {776--776},
doi = {10.1007/s11096-024-01728-8}
}
EUVIMED